Cytomegalovirus vaccine - AlphaVax/GlaxoSmithKline

Drug Profile

Cytomegalovirus vaccine - AlphaVax/GlaxoSmithKline

Alternative Names: AVX 601

Latest Information Update: 17 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AlphaVax
  • Class Antivirals; Cytomegalovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 02 Mar 2015 GlaxoSmithKline acquires Novartis' global vaccine business (excluding influenza vaccines)
  • 31 Mar 2012 Phase-I development is ongoing in USA
  • 29 Dec 2008 AlphaVax's cytomegalovirus vaccine licensed to Novartis worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top